Yes. And also remember that Helios is going to finish two trials this year, which will be before any Athx readouts but will definitely boost the stock if positive results are reported.
From their recent earnings call:
Regarding their MOVID trial or whatever it’s called (for Multistem against covid-induced ARDS), things are moving along quickly. The chaos in the hospitals is not hindering their trial: